A new study suggests that SSRIs, commonly prescribed antidepressants, may reduce biological markers of Alzheimer's disease. In a cohort of 191 individuals, AD patients on SSRIs had lower levels of plasma phosphorylated tau-181, a key indicator of disease severity.
A new study suggests that SSRIs, commonly prescribed antidepressants, may reduce biological markers of Alzheimer's disease. In a cohort of 191 individuals, AD patients on SSRIs had lower levels of plasma phosphorylated tau-181, a key indicator of disease severity.
Share this Article
Recommended